NOVABAY PHARMACEUTICALS INC (NBY)

US66987P4090 - Common Stock

0.5299  +0.03 (+5.12%)

After market: 0.51 -0.02 (-3.76%)

Fundamental Rating

2

NBY gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. NBY has a bad profitability rating. Also its financial health evaluation is rather negative. NBY has a expensive valuation and it also scores bad on growth.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

NBY had negative earnings in the past year.
In the past year NBY has reported a negative cash flow from operations.
In the past 5 years NBY always reported negative net income.
In the past 5 years NBY always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of NBY (-427.26%) is worse than 95.29% of its industry peers.
NBY's Return On Equity of -1545.24% is on the low side compared to the rest of the industry. NBY is outperformed by 86.39% of its industry peers.
Industry RankSector Rank
ROA -427.26%
ROE -1545.24%
ROIC N/A
ROA(3y)-103.8%
ROA(5y)-95.46%
ROE(3y)-240.85%
ROE(5y)-378.72%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With a decent Gross Margin value of 60.67%, NBY is doing good in the industry, outperforming 67.54% of the companies in the same industry.
In the last couple of years the Gross Margin of NBY has declined.
The Profit Margin and Operating Margin are not available for NBY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.67%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.69%
GM growth 5Y-9.44%

More info and screens

2

2. Health

2.1 Basic Checks

NBY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NBY has been reduced compared to 1 year ago.
NBY has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, NBY has a worse debt to assets ratio.

2.2 Solvency

NBY has an Altman-Z score of -66.12. This is a bad value and indicates that NBY is not financially healthy and even has some risk of bankruptcy.
NBY has a Altman-Z score of -66.12. This is amonst the worse of the industry: NBY underperforms 94.76% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that NBY is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.05, NBY is in line with its industry, outperforming 51.31% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -66.12
ROIC/WACCN/A
WACC16.74%

2.3 Liquidity

A Current Ratio of 1.15 indicates that NBY should not have too much problems paying its short term obligations.
NBY's Current ratio of 1.15 is on the low side compared to the rest of the industry. NBY is outperformed by 82.20% of its industry peers.
A Quick Ratio of 0.91 indicates that NBY may have some problems paying its short term obligations.
NBY has a Quick ratio of 0.91. This is amonst the worse of the industry: NBY underperforms 82.72% of its industry peers.
Industry RankSector Rank
Current Ratio 1.15
Quick Ratio 0.91

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 42.10% over the past year.
Looking at the last year, NBY shows a very negative growth in Revenue. The Revenue has decreased by -23.50% in the last year.
Measured over the past years, NBY shows a small growth in Revenue. The Revenue has been growing by 3.32% on average per year.
EPS 1Y (TTM)42.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.45%
Revenue 1Y (TTM)-23.5%
Revenue growth 3Y14.04%
Revenue growth 5Y3.32%
Sales Q2Q%-25.24%

3.2 Future

NBY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.92% yearly.
Based on estimates for the next years, NBY will show a small growth in Revenue. The Revenue will grow by 3.24% on average per year.
EPS Next Y98.72%
EPS Next 2Y41.15%
EPS Next 3Y25.92%
EPS Next 5YN/A
Revenue Next Year-25.07%
Revenue Next 2Y-2.82%
Revenue Next 3Y3.24%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

NBY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NBY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as NBY's earnings are expected to grow with 25.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.15%
EPS Next 3Y25.92%

More info and screens

0

5. Dividend

5.1 Amount

NBY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NOVABAY PHARMACEUTICALS INC

NYSEARCA:NBY (12/20/2024, 8:26:36 PM)

After market: 0.51 -0.02 (-3.76%)

0.5299

+0.03 (+5.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners0.24%
Inst Owner Change991.7%
Ins Owners0.01%
Ins Owner Change0%
Market Cap2.59M
Analysts83.33
Price Target3.8 (617.12%)
Short Float %1.5%
Short Ratio0.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-8.93%
Min EPS beat(2)-10.73%
Max EPS beat(2)-7.13%
EPS beat(4)1
Avg EPS beat(4)-88.95%
Min EPS beat(4)-338.94%
Max EPS beat(4)0.99%
EPS beat(8)3
Avg EPS beat(8)-88.44%
EPS beat(12)4
Avg EPS beat(12)-75.68%
EPS beat(16)7
Avg EPS beat(16)-57.37%
Revenue beat(2)0
Avg Revenue beat(2)-16.26%
Min Revenue beat(2)-24.67%
Max Revenue beat(2)-7.85%
Revenue beat(4)1
Avg Revenue beat(4)-11.15%
Min Revenue beat(4)-24.67%
Max Revenue beat(4)8.53%
Revenue beat(8)2
Avg Revenue beat(8)-7.74%
Revenue beat(12)4
Avg Revenue beat(12)-6.68%
Revenue beat(16)5
Avg Revenue beat(16)-5.58%
PT rev (1m)-48.97%
PT rev (3m)-89.02%
EPS NQ rev (1m)-29.41%
EPS NQ rev (3m)-29.41%
EPS NY rev (1m)0%
EPS NY rev (3m)58.65%
Revenue NQ rev (1m)-29.51%
Revenue NQ rev (3m)-29.51%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-10.75%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.23
P/FCF N/A
P/OCF N/A
P/B 2.42
P/tB 2.42
EV/EBITDA N/A
EPS(TTM)-53.5
EYN/A
EPS(NY)-0.85
Fwd EYN/A
FCF(TTM)-0.93
FCFYN/A
OCF(TTM)-0.92
OCFYN/A
SpS2.29
BVpS0.22
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -427.26%
ROE -1545.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.67%
FCFM N/A
ROA(3y)-103.8%
ROA(5y)-95.46%
ROE(3y)-240.85%
ROE(5y)-378.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.69%
GM growth 5Y-9.44%
F-Score4
Asset Turnover2.89
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.88%
Cap/Sales 0.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.15
Quick Ratio 0.91
Altman-Z -66.12
F-Score4
WACC16.74%
ROIC/WACCN/A
Cap/Depr(3y)24.65%
Cap/Depr(5y)32.5%
Cap/Sales(3y)0.5%
Cap/Sales(5y)0.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.45%
EPS Next Y98.72%
EPS Next 2Y41.15%
EPS Next 3Y25.92%
EPS Next 5YN/A
Revenue 1Y (TTM)-23.5%
Revenue growth 3Y14.04%
Revenue growth 5Y3.32%
Sales Q2Q%-25.24%
Revenue Next Year-25.07%
Revenue Next 2Y-2.82%
Revenue Next 3Y3.24%
Revenue Next 5YN/A
EBIT growth 1Y35.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.97%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y54.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y53.72%
OCF growth 3YN/A
OCF growth 5YN/A